Reading the tape
NASDAQ: INAB
IN8bio, Inc.
Healthcare · Biotechnology
Market Cap
$7.46M
52w High
$5.61
52w Low
$1.17
P/E
-0.36
Volume
76.63K
Outstanding Shares
4.64M
Price vs Fundamentals
Why The Stock Is Moving
Likely multiple compressionModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -67.8%FCF (TTM): 47.76%
What changed
The stock fell 67.8% over the last year. Free cash flow grew 47.76% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read is wrong if revenue rolls over, margins compress again, or free cash flow keeps deteriorating. In that case the selloff would be catching up with weaker business quality rather than just a lower multiple.
Company profile
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers.
CEOTai-Wei
SectorHealthcare
IndustryBiotechnology
Employees18
IPO dateJul 30, 2021
Valuation
Forward P/E—
EV/EBITDA0.81
Enterprise value-$14.07M
Stock splits
Jun 6, 2025↓ Reverse
Every 30 shares became 1
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-70.54%▲66.45%vs FY2024
Analyst consensus
RatingBuy
Target price$4.00▲148.45%
3
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est -$0.59 · Revenue est —
View